Search
MK-0482
go.drugbank.com/drugs/DB17453InvestigationalMK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
NTx-265
go.drugbank.com/drugs/DB05649InvestigationalIn May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigationallymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. … It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death.
Deracoxib
go.drugbank.com/drugs/DB11395ExperimentalVet approvedDeramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with orthopedic surgery in dogs. … Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs.
SBT-100
go.drugbank.com/drugs/DB17215ExperimentalSBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb).
Normethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitNormethadone is used as an opioid antitussive in combination with [DB11610]. It is marketed in Canada by Valeant under the tradename Cophylac.
DDP-225
go.drugbank.com/drugs/DB05642InvestigationalDynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003. … Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system.
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591] … [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.
Iopanoic acid
go.drugbank.com/drugs/DB08946ApprovedWithdrawnIopanoic acid contains iodine and is useful as a contrast medium in cholecystography.
Categories: Compounds used in a research, industrial, or household settingLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).